<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48567">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473952</url>
  </required_header>
  <id_info>
    <org_study_id>GTI1408</org_study_id>
    <nct_id>NCT02473952</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics Inc.</source>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to
      placebo in subjects with MG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the efficacy of IGIV-C in subjects with generalized
      myasthenia gravis (MG) on standard of care treatment at study entry in terms of improvement
      in MG symptoms as measured by the mean change in Quantitative Myasthenia Gravis (QMG) score
      from Baseline (Week 0) to Week 24 as compared to placebo.

      The safety objective of this study is to evaluate the safety and tolerability of IGIV-C
      loading dose of 2 g/kg followed by 7 maintenance dosages of 1 g/kg every 3 weeks through
      Week 21 in subjects with MG.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in myasthenia gravis (MG) symptoms as measured by the mean change in QMG score.</measure>
    <time_frame>from Baseline (Week 0) to Week 24</time_frame>
    <description>To measure improvement in MG symptoms by the mean change in Quantitative myasthenia gravis (QMG) score from Baseline (Week 0) to Week 24 as compared to placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Myasthenia Gravis, Generalized</condition>
  <arm_group>
    <arm_group_label>IGIV-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.
An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGIV-C</intervention_name>
    <description>IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified</description>
    <arm_group_label>IGIV-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anti-acetylcholine receptor (AChR) antibody positive

          -  Confirmed diagnosis of generalized myasthenia gravis (MG).

          -  Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or
             IVa inclusive at Screening.

          -  QMG &gt;= 10 at Screening. Note: Subjects who only have a history of ocular MG may not
             enroll.

          -  Receiving standard of care MG treatment at a stable dose consisting of any one of the
             following for the time intervals delineated below (time intervals apply to
             medications and maintenance of stable dose level):

               1. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks
                  prior to Screening and no immunosuppressants

               2. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks
                  prior to Screening AND/OR only one of the following:

                    1. Prednisone (up to 60 mg/day or equivalent) for at least 2 months prior to
                       Screening, OR

                    2. Azathioprine for at least 6 months prior to Screening, OR

                    3. Mycophenolate mofetil for at least 6 months prior to Screening, OR

                    4. Methotrexate for at least 6 months prior to Screening, OR

                    5. Cyclosporine or tacrolimus for at least 3 months prior to Screening

               3. Cholinesterase inhibitor (pyridostigmine or equivalent) for at least 2 weeks
                  prior to Screening AND/OR prednisone (up to 60 mg/day or equivalent) for at
                  least one month prior to Screening and only one of the following:

                    1. Azathioprine for at least 6 months prior to Screening, OR

                    2. Mycophenolate mofetil for at least 6 months prior to Screening, OR

                    3. Methotrexate for at least 6 months prior to Screening, OR

                    4. Cyclosporine or tacrolimus for at least 3 months prior to Screening

        Exclusion Criteria:

          -  Have received cyclophosphamide or any other immunosuppressive agent apart from the
             ones allowed per inclusion criteria within the past 6 months

          -  Any change in MG treatment regimen between Screening (Week -3, Visit 0) and Baseline
             (Week 0, Visit 1)

          -  Greater than two point change in QMG score, increased or decreased, between Screening
             (Week -3, Visit 0) and Baseline (Week 0, Visit 1)

          -  Any episode of myasthenic crisis in the one month prior to Screening

          -  Evidence of malignancy within the past 5 years (non-melanoma skin cancer, carcinoma
             in situ of cervix is allowed) or thymoma potentially requiring surgical intervention
             during the course of the trial (intent to perform thymectomy)

          -  Thymectomy within the preceding 6 months

          -  Rituximab, belimumab, eculizumab or any monoclonal antibody used for immunomodulation
             within the past 12 months

          -  Have received immune globulin (Ig) treatment given by intravenous (IV), subcutaneous,
             or intramuscular route within the last 3 months

          -  Current known hyperviscosity or hypercoagulable state

          -  Currently receiving anti-coagulation therapy (vitamin K antagonists, nonvitamin K
             antagonist oral anticoagulants [e.g., dabigatran etexilate, rivaroxaban, edoxaban,
             and apixaban], parenteral anticoagulants [e.g., fondaparinux]). Note that oral
             anti-platelet agents are allowed (e.g., aspirin, clopidogrel, ticlodipine)

          -  Documented diagnosis of thrombotic complications to polyclonal intravenous
             immunoglobulin (IVIg) therapy in the past

          -  History of recent (within the last year) myocardial infarction or stroke

          -  Uncontrolled congestive heart failure; embolism; or historically documented (within
             the last year) electrocardiogram (ECG) changes indicative of myocardial ischemia or
             atrial fibrillation

          -  History of chronic alcoholism or illicit drug abuse (addiction) in the 12 months
             preceding the Screening/Week -3 (Visit 0)

          -  Plasma exchange (PLEX) performed within the last 2 months

          -  Renal impairment (i.e., serum creatinine exceeds more than 1.5 times the upper limit
             of normal [ULN] for the expected normal range for the testing laboratory).

          -  Hemoglobin levels less than 9 g per dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rhonda Griffin, BSN</last_name>
    <phone>919-316-6993</phone>
    <email>Rhonda.Griffin@grifols.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Neurological Associates, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynette McKinney</last_name>
    </contact>
    <investigator>
      <last_name>Todd Levine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Veena</last_name>
    </contact>
    <investigator>
      <last_name>Tahseen Mozaffar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Nye, BS</last_name>
    </contact>
    <investigator>
      <last_name>Richard Nowak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida at Shands Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Vickery</last_name>
    </contact>
    <investigator>
      <last_name>Michael Pulley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Harvey</last_name>
    </contact>
    <contact_backup>
      <last_name>Rita Tamcsu</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tuan Vu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Quarles</last_name>
    </contact>
    <investigator>
      <last_name>Michael Rivner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Guingrich</last_name>
    </contact>
    <contact_backup>
      <last_name>Angela Micheels</last_name>
    </contact_backup>
    <investigator>
      <last_name>Robert Pascuzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathyrn Johns</last_name>
    </contact>
    <investigator>
      <last_name>Mamatha Pasnoor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Furnari</last_name>
    </contact>
    <contact_backup>
      <last_name>Nancy Reilly</last_name>
    </contact_backup>
    <investigator>
      <last_name>Nizar Souayah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Paras</last_name>
    </contact>
    <contact_backup>
      <last_name>Kim Arreum</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thomas Brannagan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Beck</last_name>
    </contact>
    <contact_backup>
      <last_name>Lisa Gauger</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Guptill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Agriesti</last_name>
    </contact>
    <investigator>
      <last_name>Miriam Freimer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Fedor</last_name>
    </contact>
    <contact_backup>
      <last_name>Luanne Balestrucci</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marinos Dalakas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Lay, Jr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Lisa Thompson</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ericka Simpson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Lucy</last_name>
    </contact>
    <investigator>
      <last_name>Rup Tandan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Strom</last_name>
    </contact>
    <investigator>
      <last_name>Jane Distad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Tilkin</last_name>
    </contact>
    <investigator>
      <last_name>Philip Van Damme</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Hulley</last_name>
    </contact>
    <contact_backup>
      <last_name>Wilma Koopman</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Nicolle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network (UHN) - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Ng</last_name>
    </contact>
    <investigator>
      <last_name>Vera Bril</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'université de Montréal (CHUM) hospital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute Clinical Research Unit</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Dept of Neurologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislava Toncrova</last_name>
    </contact>
    <investigator>
      <last_name>Josef Bednarik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milada Sedlakova</last_name>
    </contact>
    <investigator>
      <last_name>Petr Hon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Raats</last_name>
    </contact>
    <investigator>
      <last_name>Toomas Toomsoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hôpital de l'Archet 1, Ctre de Réf Maladies Neuromusculaires et SLA</name>
      <address>
        <city>Nice cedex 3</city>
        <state>Alpes Maritimes</state>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Moutarde</last_name>
    </contact>
    <investigator>
      <last_name>Sabrina Sacconi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - Nouvel Hôpital Civil, Clinique Neurologique</name>
      <address>
        <city>Strasbourg cedex</city>
        <state>Bas Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Barun</last_name>
    </contact>
    <investigator>
      <last_name>Christine Tranchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan, Service de Neurologie Générale</name>
      <address>
        <city>Toulouse cedex 9</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Bucciarelli</last_name>
    </contact>
    <investigator>
      <last_name>David Brassat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique Pierre Wertheimer, Neuro-musculaire - Electromyographie</name>
      <address>
        <city>Bron cedex</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Merle</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Vial</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Regensburg, Parent</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina Kammermaier</last_name>
    </contact>
    <investigator>
      <last_name>Berthold Schalke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Goettingen, Parent</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margret Schwarz</last_name>
    </contact>
    <investigator>
      <last_name>Jens Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln, Neurologie und Psychiatrie</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Ulrike Vay</last_name>
    </contact>
    <investigator>
      <last_name>Michael Schroeter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Doelau, Klinik fuer Neurologie</name>
      <address>
        <city>Halle</city>
        <state>Sachsen Anhalt</state>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Hochweld</last_name>
    </contact>
    <investigator>
      <last_name>Frank Hoffmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brit Larsson</last_name>
    </contact>
    <investigator>
      <last_name>Ulrike Reuner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena, Klinik fuer Neurologie</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>7747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandy Arnold</last_name>
    </contact>
    <investigator>
      <last_name>Julian Grosskreutz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik fuer Neurologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Otto</last_name>
    </contact>
    <investigator>
      <last_name>Tim Magnus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Neurologiai Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klara Faust</last_name>
    </contact>
    <investigator>
      <last_name>Csilla Rozsa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz, Neurologia es Stroke Osztaly</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zita Biro</last_name>
    </contact>
    <investigator>
      <last_name>Gyula Panczel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Konyane</last_name>
    </contact>
    <investigator>
      <last_name>Laszlo Vecsei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Balnyte</last_name>
    </contact>
    <investigator>
      <last_name>Antanas Vaitkus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Dept of Neurology</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Kazmierska</last_name>
    </contact>
    <investigator>
      <last_name>Malgorzata Bilinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justina Wites</last_name>
    </contact>
    <investigator>
      <last_name>Andrzej Szczudlik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>III Szpital Miejski w Lodzi im. Dr K. Jonschera</name>
      <address>
        <city>Lodz</city>
        <zip>93-113</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulina Budzinska</last_name>
    </contact>
    <investigator>
      <last_name>Tomasz Berkowicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny, Dept of Neurology</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Szczudlik</last_name>
    </contact>
    <investigator>
      <last_name>Anna Kostera-Pruszczyk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>June 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
